title: MMP-28 as a regulator of myelination.
abstract: BACKGROUND
  Matrix metalloproteinase-28 (MMP-28) is a poorly understood member of the matrix metalloproteinase family. Metalloproteinases are important mediators in the development of the nervous system and can contribute to the maturation of the neural micro-environment.
  
  
  RESULTS
  MMP-28 added to myelinating rat dorsal root ganglion (DRG) co-cultures reduces myelination and two antibodies targeted to MMP-28 (pAb180 and pAb183) are capable of binding MMP-28 and inhibiting its activity in a dose-dependent manner. Addition of 30 nM pAb180 or pAb183 to rat DRG cultures resulted in the 2.6 and 4.8 fold enhancement of myelination respectively while addition of MMP-28 to DRG co-cultures resulted in enhanced MAPK, ErbB2 and ErbB3 phosphorylation. MMP-28 protein expression was increased within demyelinated lesions of mouse experimental autoimmune encephalitis (EAE) and human multiple sclerosis lesions compared to surrounding normal tissue.
  
  
  CONCLUSIONS
  MMP-28 is upregulated in conditions of demyelination in vivo, induces signaling in vitro consistent with myelination inhibition and, neutralization of MMP-28 activity can enhance myelination in vitro. These results suggest inhibition of MMP-28 may be beneficial under conditions of dysmyelination.
authors.affiliation: Biotechnology Discovery Research, Lilly Corporate Center, Indianapolis, IN 46225, USA. sean.werner@sbcglobal.net
authors.forename: Sean R
authors.initials: SR
authors.lastname: Werner
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Dotzlaf
authors.forename: Rosamund C
authors.initials: RC
authors.lastname: Smith
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001369:Axons / Q000187:drug effects / Q000378:metabolism; D015153:Blotting, Western; D002478:Cells, Cultured; D002525:Cerebellar Cortex / Q000166:cytology / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005455:Fluorescent Antibody Technique; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D053505:Matrix Metalloproteinases, Secreted / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009103:Multiple Sclerosis / Q000378:metabolism / Q000473:pathology; D009186:Myelin Sheath / Q000187:drug effects / Q000378:metabolism*; D018992:Myelin-Associated Glycoprotein / Q000378:metabolism; D011247:Pregnancy; D011485:Protein Binding; D051381:Rats; D020318:Rats, Long-Evans; D015398:Signal Transduction / Q000187:drug effects; D013116:Spinal Cord / Q000378:metabolism / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D018992:Myelin-Associated Glycoprotein; C424663:MMP28 protein, human; D053505:Matrix Metalloproteinases, Secreted
references.citation: J Neurol Sci. 2006 Jun 15;245(1-2):201-10
references.pmid: 16682057
references.citation: Dev Dyn. 2007 Oct;236(10):2852-64
references.pmid: 17823957
references.citation: J Cell Sci. 2006 Sep 15;119(Pt 18):3856-65
references.pmid: 16940349
references.citation: Nature. 1989 Nov 23;342(6248):430-3
references.pmid: 2586612
references.citation: Neurosci Lett. 1995 Dec 15;201(3):223-6
references.pmid: 8786845
references.citation: Sci STKE. 2006 Mar 07;2006(325):pe11
references.pmid: 16522871
references.citation: Neuron. 2005 Sep 1;47(5):681-94
references.pmid: 16129398
references.citation: J Neurosci. 2000 Jun 15;20(12):4635-45
references.pmid: 10844033
references.citation: Bioessays. 2000 Nov;22(11):987-96
references.pmid: 11056475
references.citation: Nat Rev Neurosci. 2001 Jul;2(7):502-11
references.pmid: 11433375
references.citation: Neuroscience. 2007 Oct 26;149(2):328-37
references.pmid: 17900814
references.citation: Science. 1934 Apr 20;79(2051):363
references.pmid: 17741794
references.citation: J Neurosci. 2004 Jul 28;24(30):6724-32
references.pmid: 15282275
references.citation: Biol Psychiatry. 2006 Jul 15;60(2):132-40
references.pmid: 16442083
references.citation: J Neurosci Res. 2003 Jun 1;72(5):565-73
references.pmid: 12749021
references.citation: Brain. 2002 Sep;125(Pt 9):1972-9
references.pmid: 12183343
references.citation: Anat Rec. 1968 Jul;161(3):337-51
references.pmid: 5685014
references.citation: Nat Med. 2006 Aug;12(8):961-6
references.pmid: 16892039
references.citation: J Neurosci. 2006 Mar 22;26(12):3079-86
references.pmid: 16554459
references.citation: Anat Rec. 1972 Jan;172(1):1-14
references.pmid: 5007368
references.citation: Nat Rev Neurosci. 2005 Sep;6(9):671-82
references.pmid: 16136171
references.citation: J Neurosci. 2005 Mar 30;25(13):3478-87
references.pmid: 15800203
references.citation: Curr Opin Neurobiol. 2001 Jun;11(3):272-80
references.pmid: 11399424
references.citation: Nat Rev Immunol. 2007 Nov;7(11):904-12
references.pmid: 17917672
references.citation: Science. 2004 Apr 30;304(5671):700-3
references.pmid: 15044753
references.citation: Nat Neurosci. 2006 Dec;9(12):1520-5
references.pmid: 17099708
references.citation: Science. 2006 Oct 27;314(5799):664-6
references.pmid: 16990514
references.citation: Glia. 2008 Feb;56(3):284-93
references.pmid: 18080294